Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Otimizando estratégias de retenção, duração e descontinuação para farmacoterapia para transtornos por uso de opioides (RDD)

9 de novembro de 2026 atualizado por: NYU Langone Health

NIDA-CTN-0100: Otimizando estratégias de retenção, duração e descontinuação para farmacoterapia para transtornos por uso de opioides (RDD)

This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

The main objectives of this study are:

  1. To test strategies to improve retention in treatment on medications for opioid use disorder (MOUD), among patients initiating treatment for OUD.
  2. To test strategies to improve outcomes among patients who have achieved stable remission on MOUD and want to discontinue MOUD.
  3. To develop models to predict who is able to discontinue MOUD without relapse, based on patient characteristics, including duration of MOUD prior to discontinuation.

The study will have a multicenter, randomized, pragmatic non-blinded design. The study has two phases, a Retention Phase and a Discontinuation Phase.

Tipo de estudo

Intervencional

Inscrição (Real)

1516

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)
    • California
      • Tarzana, California, Estados Unidos, 91356
        • Tarzana Treatment Centers, Inc.
    • Connecticut
      • Bridgeport, Connecticut, Estados Unidos, 06610
        • Liberation Programs, Inc.
    • Florida
      • Clearwater, Florida, Estados Unidos, 33760
        • Operation PAR
      • Jacksonville, Florida, Estados Unidos, 32204
        • Gateway Community Services
      • Orlando, Florida, Estados Unidos, 32806
        • Aspire Health Partners
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21229
        • Mountain Manor / Maryland Treatment Centers
    • Massachusetts
      • Belmont, Massachusetts, Estados Unidos, 02478
        • McLean Hospital
      • Fall River, Massachusetts, Estados Unidos, 02720
        • Stanley Street Treatment and Resources, Inc.
      • Newton, Massachusetts, Estados Unidos, 02458
        • Square Medical Group, LLC
    • Missouri
      • Cape Girardeau, Missouri, Estados Unidos, 63703
        • Gibson Center for Behavioral Change
    • New Hampshire
      • Lebanon, New Hampshire, Estados Unidos, 03766
        • Dartmouth Hitchcock - ATP
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87106
        • University of New Mexico Addiction and Substance Abuse Program
    • New York
      • New York, New York, Estados Unidos, 10016
        • Bellevue Hospital Center
    • Oregon
      • Roseburg, Oregon, Estados Unidos, 97470
        • Adapt Integrated Health Care
      • Winston, Oregon, Estados Unidos, 97496
        • Adapt Integrated Health Care
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15213
        • Center for Psychiatric and Chemical Dependency Services (CPCDS)
      • Pittsburgh, Pennsylvania, Estados Unidos, 15219
        • Internal Medicine Recovery Engagement Program (IM-REP)
    • South Carolina
      • Conway, South Carolina, Estados Unidos, 29526
        • Shoreline Behavioral Health Services
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84108
        • Huntsman Mental Health Institute / University of Utah
    • West Virginia
      • Morgantown, West Virginia, Estados Unidos, 26505
        • Chestnut Ridge Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria for Retention Phase:

  1. 18 years of age or older;
  2. Meet DSM-5 criteria for current opioid use disorder (heroin, fentanyl or other synthetic opioids, and/or prescription opioids);
  3. Seeking treatment for opioid use disorder and choosing either buprenorphine (BUP) or extended-release injection naltrexone (XR-NTX);
  4. If choosing buprenorphine, willing to be randomized to SL-BUP-16mg, SL-BUP-32mg, or XR-BUP;
  5. Willing to be randomized to either MM (standard Medical Management plus counseling treatment as usual available at the site) or MMR (MM plus usual counseling and access to an app delivering CM + CBT);
  6. In good-enough general health (meaning good enough health to be in outpatient treatment) as determined by the study medical clinician on the basis of medical history, review of systems, and physical/mental status exam, to permit treatment with XR-NTX or BUP;
  7. Willing and able to provide written informed consent;
  8. Able to speak English sufficiently to understand the study procedures;
  9. If female of childbearing potential, willing to practice an effective method of birth control for the duration of participation in the study (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).

Exclusion Criteria for Retention Phase:

  1. Serious medical, psychiatric, or co-occurring substance use disorder or concomitant medication that, in the opinion of the study medical clinician, makes the patient not appropriate for outpatient treatment with buprenorphine or XR-NTX, but instead requires a higher or different level of care. Examples include:

    1. Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
    2. Severe, untreated or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
    3. Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use, requiring a different level of care (e.g., hospitalization);
  2. Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);

  3. Known allergy or sensitivity to preferred medication or its components;

  4. Maintenance on methadone at the time of signing consent;

  5. For those preferring XR-NTX, presence of pain of sufficient severity as to require ongoing pain management with opioids;

  6. For those preferring XR-NTX, body habitus that, in the judgment of the study physician, precludes safe intramuscular injection of XR-NTX (e.g., BMI>40, excess fat tissue over the buttocks, emaciation);

  7. If female, currently pregnant or breastfeeding or planning on conception;

  8. Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;

  9. Have used the reSET-O or CHESS Connections mHealth apps in the 3 months prior to consent;

  10. Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area).

Inclusion Criteria for Discontinuation Phase:

  1. 18 years of age or older;
  2. Have been receiving buprenorphine for OUD for at least the past year or XR-NTX pharmacotherapy for OUD for at least the past 6 months prior to consent for the Discontinuation Phase;
  3. Express the desire to discontinue MOUD after a shared decision-making discussion with the treating provider;
  4. Meet stability criteria, i.e., have abstained from opioids (other than buprenorphine), cocaine, methamphetamine, and non-prescribed benzodiazepines for the past ≥12 weeks, and do not meet DSM-5 criteria for current (≥12 weeks) alcohol use disorder (participants with cannabis use will be eligible);
  5. If currently taking buprenorphine, are willing to take either SL-BUP or XR-BUP if randomized to that condition;
  6. Willing to be randomized to either MM or to MMD;
  7. Able to provide written informed consent after discussion with their provider regarding the risks of discontinuation;
  8. Able to speak English sufficiently to understand the study procedures;
  9. If female of childbearing potential, willing to practice an effective method of birth control while in the study and taking study medication (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).

Exclusion Criteria for Discontinuation Phase:

  1. Serious medical or psychiatric disorder or concomitant medication that, in the opinion of the study medical clinician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include:

    1. Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
    2. Severe, untreated, or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
  2. Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);

  3. For participants entering the study taking buprenorphine, presence of pain requiring or likely requiring ongoing pain management with buprenorphine or other opioids;

  4. If female, currently pregnant or breastfeeding or planning on conception;

  5. Use of opioids (other than buprenorphine), cocaine, methamphetamine, or non-prescribed benzodiazepines in the past 12 weeks;

  6. Meets current DSM-5 criteria for any current alcohol use disorder;

  7. Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;

  8. Have used the Connections mHealth app in the 3 months prior to consent (other than Connections in the Retention Phase);

  9. Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição fatorial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Retention: SL-BUP standard dose + MM

Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

Outros nomes:
  • Suboxone
  • buprenorfina sublingual

MM consists of standard Medical Management and the usual counseling at the treatment program.

Experimental: Retention: SL-BUP high dose + MM

High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

Outros nomes:
  • Suboxone
  • buprenorfina sublingual

MM consists of standard Medical Management and the usual counseling at the treatment program.

Experimental: Retention: XR-BUP + MM

Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

Outros nomes:
  • CAM2038
  • buprenorfina de liberação prolongada
  • Brixadi
Experimental: Retention: XR-NTX + MM

Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Monthly dosing of extended-release injectable naltrexone

Outros nomes:
  • Vivitrol
  • naltrexona de liberação prolongada
Experimental: Retention: SL-BUP standard dose + MMR

Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

Outros nomes:
  • Suboxone
  • buprenorfina sublingual

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Experimental: Retention: SL-BUP high dose + MMR

High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

Outros nomes:
  • Suboxone
  • buprenorfina sublingual

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Experimental: Retention: XR-BUP + MMR

Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

Outros nomes:
  • CAM2038
  • buprenorfina de liberação prolongada
  • Brixadi

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Experimental: Retention: XR-NTX + MMR

Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Monthly dosing of extended-release injectable naltrexone

Outros nomes:
  • Vivitrol
  • naltrexona de liberação prolongada

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Experimental: Discontinuation: Discontinue SL-BUP with SL-BUP + MM

Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

Outros nomes:
  • Suboxone
  • buprenorfina sublingual

MM consists of standard Medical Management and the usual counseling at the treatment program.

Experimental: Discontinuation: Discontinue SL-BUP with XR-BUP + MM

Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

Outros nomes:
  • CAM2038
  • buprenorfina de liberação prolongada
  • Brixadi
Experimental: Discontinuation: Discontinue XR-BUP with XR-BUP + MM

Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

Outros nomes:
  • CAM2038
  • buprenorfina de liberação prolongada
  • Brixadi
Experimental: Discontinuation: Discontinue XR-NTX with XR-NTX + MM

Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Monthly dosing of extended-release injectable naltrexone

Outros nomes:
  • Vivitrol
  • naltrexona de liberação prolongada
Experimental: Discontinuation: Discontinue SL-BUP with SL-BUP + MMD

Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

Outros nomes:
  • Suboxone
  • buprenorfina sublingual

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Experimental: Discontinuation: Discontinue SL-BUP with XR-BUP + MMD

Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

Outros nomes:
  • CAM2038
  • buprenorfina de liberação prolongada
  • Brixadi

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Experimental: Discontinuation: Discontinue XR-BUP with XR-BUP + MMD

Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

Outros nomes:
  • CAM2038
  • buprenorfina de liberação prolongada
  • Brixadi

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Experimental: Discontinuation: Discontinue XR-NTX with XR-NTX + MMD

Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Monthly dosing of extended-release injectable naltrexone

Outros nomes:
  • Vivitrol
  • naltrexona de liberação prolongada

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Retention: Continuous retention in MOUD treatment through 26 weeks
Prazo: Retention: from randomization through week 26

Binary (yes/no). Continuously enrolled in maintenance treatment on one or more of the evidence-based MOUD modalities (e.g., SL-BUP, XR-BUP, XR-NTX, or methadone maintenance) with no more than a 28-day gap on MOUD over the 26-week period.

Retention: from randomization through week 26
Discontinuation: Completed Discontinuation without Relapse
Prazo: Discontinuation: from randomization through week 24 follow up

Binary (yes/no). Discontinuing MOUD during the taper period, no return to MOUD, and no relapse to opioid use, either during the taper (up to 48 weeks for those entering on BUP or 24 weeks for those entering on XR-NTX) or during the 24 weeks after MOUD is discontinued.

Discontinuation: from randomization through week 24 follow up

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Retention KS1: Weekly opioid abstinence
Prazo: Retention: from randomization through week 26

Weekly opioid abstinence (measured by Timeline Followback, not contradicted by toxicology test). Repeated yes/no measure for each of weeks 1 through 26.

Retention: from randomization through week 26
Retention KS2: Treatment effectiveness
Prazo: Retention: at week 26

Retention treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 26.

Retention: at week 26
Retention KS3: Treatment by baseline severity
Prazo: Retention: at week 26

Treatment by baseline severity interaction where severity is indicated by the randomization stratum injection use (yes/no).

Retention: at week 26
Discontinuation KS1: Completed Discontinuation
Prazo: Discontinuation: from randomization through week 24 follow up

Completed Discontinuation without regard to relapse status

Discontinuation: from randomization through week 24 follow up
Discontinuation KS2: Relapse
Prazo: Discontinuation: from randomization through week 24 follow up

Relapse - separate binary outcome without regard to discontinuation status

Discontinuation: from randomization through week 24 follow up
Discontinuation KS3: Safety
Prazo: Discontinuation: from randomization through week 24 follow up

Safety outcomes (binary, any one or more occurrences): overdoses, all non-fatal plus fatal.

Discontinuation: from randomization through week 24 follow up
Discontinuation KS4: Treatment effectiveness
Prazo: Discontinuation: at end of taper (EoT) and week 24 follow up

Discontinuation treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 24. Measured at the end of taper (EOT): up to 24 weeks for tapers with XR-NTX and up to 48 weeks for tapers with BUP; and at the week 24 follow up (primary outcome timepoint).

Discontinuation: at end of taper (EoT) and week 24 follow up

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Edward V Nunes, MD, New York State Psychiatric Institute/Columbia University Irving Medical Center
  • Investigador principal: Roger Weiss, MD, Harvard Medical School/McLean Hospital
  • Investigador principal: John Rotrosen, MD, NYU Langone Health

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

8 de junho de 2021

Conclusão Primária (Estimado)

31 de dezembro de 2026

Conclusão do estudo (Estimado)

31 de janeiro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

29 de junho de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

6 de julho de 2020

Primeira postagem (Real)

9 de julho de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 19-01363
  • UG1DA015831 (Concessão/Contrato do NIH dos EUA)
  • CTN-0100 (Outro identificador: NIDA Clinical Trials Network)
  • UG1DA013035 (Concessão/Contrato do NIH dos EUA)
  • 20-PRS-057 (Outro identificador: Biomedical Research Alliance of New York (BRANY) sIRB)
  • 146193 (Outro identificador: FDA/IND#)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

This study will comply with the NIH Data Sharing Policy and Implementation Guidance (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm) and (for HEAL-funded studies) the HEAL Public Access and Data Sharing Policy (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/research/heal-public-access-data-sharing-policy).

Primary data for this study will be available to the public in the NIDA data repository. For more details on data sharing please visit https://datashare.nida.nih.gov/.

The primary outcome(s) publication will be included along with study underlying primary data in the data share repository, and it will also be deposited in PubMed Central http://www.pubmedcentral.nih.gov/ per NIH Policy (http://publicaccess.nih.gov/).

Prazo de Compartilhamento de IPD

Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .